home / openregs

documents

Regulatory documents from Regulations.gov including rules, proposed rules, notices, and supporting materials.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

comment_end_date
A FULL UTC INSTANT, not a calendar date, despite the column name: '2026-08-29T03:59:59Z' is 11:59:59 PM EASTERN on 2026-08-28. Federal comment periods close at 11:59:59 PM Eastern, so the UTC calendar date is ONE DAY LATER than the official deadline on every end-of-day close — 444,689 of the 444,690 populated rows (measured 2026-09-06). Convert to America/New_York before presenting a deadline, and compare with julianday(comment_end_date) > julianday('now'): a plain > datetime('now') is a TEXT comparison between two different formats and keeps already-closed dockets matching for up to ~20 hours. The sibling column on open_comments.documents WAS corrected to an Eastern calendar date (queue #498); this one is unchanged and still an instant — the two databases do not agree on grain. (queue #644)
comment_start_date
A FULL UTC INSTANT, not a calendar date, despite the column name — same grain as comment_end_date on this table. Convert to America/New_York before presenting it. (queue #644)

1,728,051 rows sorted by posted_date descending

✎ View and edit SQL

This data as json, CSV (advanced)

posted_year >30

  • 2018 106,690
  • 2016 98,713
  • 2019 91,918
  • 2015 80,499
  • 2024 78,228
  • 2023 73,203
  • 2017 72,886
  • 2021 71,789
  • 2022 71,318
  • 2020 69,829
  • 2006 68,985
  • 2014 65,338
  • 2007 63,922
  • 2011 61,511
  • 2025 61,376
  • 2013 61,338
  • 2012 60,059
  • 2010 56,532
  • 2008 55,828
  • 2009 54,066
  • 2004 47,970
  • 2005 47,206
  • 2026 35,428
  • 2003 34,977
  • 2002 28,411
  • 2001 20,449
  • 2000 19,990
  • 1999 17,091
  • 1998 14,407
  • 1995 13,108
  • …

agency_id >30

  • EPA 495,227
  • FDA 230,393
  • DOT 194,125
  • FAA 192,831
  • BIS 56,803
  • FMCSA 49,212
  • SEC 41,970
  • PHMSA 38,191
  • FERC 37,545
  • USCG 32,732
  • OSHA 31,908
  • NHTSA 28,862
  • FRA 28,087
  • FWS 16,108
  • NRC 15,664
  • NOAA 15,286
  • USTR 13,623
  • ITA 13,273
  • NIH 13,161
  • MARAD 11,632
  • FCC 10,117
  • ED 9,633
  • FEMA 9,340
  • VA 7,743
  • CMS 7,157
  • HUD 7,140
  • APHIS 6,249
  • DOE 5,349
  • USPS 5,323
  • CPSC 4,957
  • …

document_type 5

  • Other 659,070
  • Supporting & Related Material 621,397
  • Notice 316,679
  • Rule 88,228
  • Proposed Rule 42,677
id agency_id docket_id title document_type subtype posted_date ▲ posted_year posted_month comment_start_date comment_end_date last_modified fr_doc_num open_for_comment withdrawn object_id
FWS-HQ-IA-2026-3070-0010 FWS Receipt of Application (Houston Zoo) FWS-HQ-IA-2026-3070 Applicant: Houston Zoo, Houston, TX; Permit No. PER34597820 Supporting & Related Material   2026-09-15T04:00:00Z 2026 9     2026-09-15T18:18:18Z   0 0 09000064b9557a01
FWS-HQ-IA-2026-3070-0011 FWS Receipt of Application (Houston Zoo) FWS-HQ-IA-2026-3070 Applicant: National Aviary in Pittsburgh, Pittsburgh, PA; Permit No. PER34649881 Supporting & Related Material   2026-09-15T04:00:00Z 2026 9     2026-09-15T18:18:18Z   0 0 09000064b9557a02
FWS-HQ-IA-2026-3070-0007 FWS Receipt of Application (Houston Zoo) FWS-HQ-IA-2026-3070 Applicant: Meyers Ranch LLC, El Paso, TX; Permit No. PER34533557 Supporting & Related Material   2026-09-15T04:00:00Z 2026 9     2026-09-15T18:18:17Z   0 0 09000064b954f714
FWS-HQ-IA-2026-3070-0005 FWS Receipt of Application (Houston Zoo) FWS-HQ-IA-2026-3070 Applicant: Lesley Hathaway, Portland, IN; Permit No. PER34952786 Supporting & Related Material   2026-09-15T04:00:00Z 2026 9     2026-09-15T18:18:17Z   0 0 09000064b954f711
FWS-HQ-IA-2026-3070-0002 FWS Receipt of Application (Houston Zoo) FWS-HQ-IA-2026-3070 Applicant: Richard Colter Calderwood, Liberty Hill, TX; Permit No. PER34938259 Supporting & Related Material   2026-09-15T04:00:00Z 2026 9     2026-09-15T18:18:16Z   0 0 09000064b954f70e
FWS-HQ-IA-2026-3070-0004 FWS Receipt of Application (Houston Zoo) FWS-HQ-IA-2026-3070 Applicant: Midwestern University, Glendale, AZ; Permit No. PER29395039 Supporting & Related Material   2026-09-15T04:00:00Z 2026 9     2026-09-15T18:18:17Z   0 0 09000064b954f710
FWS-HQ-IA-2026-3070-0001 FWS Receipt of Application (Houston Zoo) FWS-HQ-IA-2026-3070 Foreign Endangered Species; Receipt of Permit Applications Notice   2026-09-15T04:00:00Z 2026 9 2026-09-15T04:00:00Z 2026-10-16T03:59:59Z 2026-09-15T18:18:05Z 2026-18845 1 0 09000064b955ac9c
FWS-HQ-IA-2026-3070-0013 FWS Receipt of Application (Houston Zoo) FWS-HQ-IA-2026-3070 Applicant: Brian Thomas Spielmann, Hayward, WI; Permit No. PER34950820 Supporting & Related Material   2026-09-15T04:00:00Z 2026 9     2026-09-15T18:18:19Z   0 0 09000064b955201f
FWS-HQ-IA-2026-3070-0006 FWS Receipt of Application (Houston Zoo) FWS-HQ-IA-2026-3070 Applicant: Brett Wiggs, Hamilton, TX; Permit No. PER34949139 Supporting & Related Material   2026-09-15T04:00:00Z 2026 9     2026-09-15T18:18:17Z   0 0 09000064b954f712
FWS-HQ-IA-2026-3070-0012 FWS Receipt of Application (Houston Zoo) FWS-HQ-IA-2026-3070 Applicant: Columbus Zoo and Aquarium, Powell, OH; Permit No. PER30305836 Supporting & Related Material   2026-09-15T04:00:00Z 2026 9     2026-09-15T18:18:18Z   0 0 09000064b9557a03
FWS-HQ-IA-2026-3070-0009 FWS Receipt of Application (Houston Zoo) FWS-HQ-IA-2026-3070 Applicant: Meyers Ranch LLC, El Paso, TX; Permit No. PER34533558 Supporting & Related Material   2026-09-15T04:00:00Z 2026 9     2026-09-15T18:18:18Z   0 0 09000064b9557a00
FWS-HQ-IA-2026-3070-0008 FWS Receipt of Application (Houston Zoo) FWS-HQ-IA-2026-3070 Applicant: Edgar DeHart Jr., Galax, VA; Permit No. PER34955610 Supporting & Related Material   2026-09-15T04:00:00Z 2026 9     2026-09-15T18:18:18Z   0 0 09000064b954f715
FWS-HQ-IA-2026-3070-0003 FWS Receipt of Application (Houston Zoo) FWS-HQ-IA-2026-3070 Applicant: Terry Reinke, Longmont, CO; Permit No. PER34947683 Supporting & Related Material   2026-09-15T04:00:00Z 2026 9     2026-09-15T18:18:16Z   0 0 09000064b954f70f
FDA-2026-P-8286-0003 FDA Request that the FDA determine whether DDAVP (desmopressin acetate) Nasal Spray, 0.01 mg/Spray (Needs No Refrigeration), Product No. 003 approved under New Drug Application (NDA) number 017922, held by Ferring Pharmaceuticals, Inc., has been voluntarily withdrawn for reasons of safety or effectiveness. FDA-2026-P-8286 Withdrawal Request from Hyman, Phelps & McNamara, P.C. Other Withdrawal 2026-09-15T04:00:00Z 2026 9 2026-09-15T04:00:00Z   2026-09-16T00:37:09Z   0 0 09000064b9560da6
FDA-2026-P-10785-0001 FDA Requests that the FDA declare that the drug products Famotidine Capsules, 20 mg and 40 mg, are suitable for consideration in an Abbreviated New Drug Application. FDA-2026-P-10785 Suitability Petition from Hyman, Phelps & McNamara, P.C. Other Petition(s) 2026-09-15T04:00:00Z 2026 9 2026-09-15T04:00:00Z   2026-09-16T00:11:56Z   1 0 09000064b9562c0b
FDA-2026-P-10785-0005 FDA Requests that the FDA declare that the drug products Famotidine Capsules, 20 mg and 40 mg, are suitable for consideration in an Abbreviated New Drug Application. FDA-2026-P-10785 Attachment 3 Supporting & Related Material Background Material 2026-09-15T04:00:00Z 2026 9     2026-09-16T00:12:09Z   0 0 09000064b9560857
FDA-2026-H-10567-0001 FDA DAB Civil Money Penalty; Donaciano Macareno and Candido Macareno d/b/a St. James Deli FDA-2026-H-10567 Complaint Other Complaint 2026-09-15T04:00:00Z 2026 9 2026-09-15T04:00:00Z   2026-09-15T23:29:59Z   0 0 09000064b956322f
FDA-2026-P-10693-0011 FDA Requests that the FDA rescind their decision to file Zydus’s section 505(b)(2) applications for apparent duplicates of DESCOVY and VEMLIDY and refuse to grant either of Zydus’s products an A-rating reflecting a determination of therapeutic equivalence, should such a determination become relevant. FDA-2026-P-10693 Appendix 1 Exhibit 7 - Hoser 2025 Supporting & Related Material Background Material 2026-09-15T04:00:00Z 2026 9     2026-09-15T17:45:45Z   0 0 09000064b95244bf
FDA-2026-P-10693-0010 FDA Requests that the FDA rescind their decision to file Zydus’s section 505(b)(2) applications for apparent duplicates of DESCOVY and VEMLIDY and refuse to grant either of Zydus’s products an A-rating reflecting a determination of therapeutic equivalence, should such a determination become relevant. FDA-2026-P-10693 Appendix 1 Exhibit 6 - Ge 2024 Supporting & Related Material Background Material 2026-09-15T04:00:00Z 2026 9     2026-09-15T17:45:41Z   0 0 09000064b95244be
FDA-2026-P-10693-0006 FDA Requests that the FDA rescind their decision to file Zydus’s section 505(b)(2) applications for apparent duplicates of DESCOVY and VEMLIDY and refuse to grant either of Zydus’s products an A-rating reflecting a determination of therapeutic equivalence, should such a determination become relevant. FDA-2026-P-10693 Appendix 1 Exhibit 2 part 2 - XtalPi Report References Supporting & Related Material Background Material 2026-09-15T04:00:00Z 2026 9     2026-09-15T17:45:25Z   0 0 09000064b95244ba
FDA-2026-P-10693-0003 FDA Requests that the FDA rescind their decision to file Zydus’s section 505(b)(2) applications for apparent duplicates of DESCOVY and VEMLIDY and refuse to grant either of Zydus’s products an A-rating reflecting a determination of therapeutic equivalence, should such a determination become relevant. FDA-2026-P-10693 Appendix 1 - Mercado Declaration Supporting & Related Material Background Material 2026-09-15T04:00:00Z 2026 9     2026-09-15T17:45:08Z   0 0 09000064b95244b7
FDA-2026-P-10693-0087 FDA Requests that the FDA rescind their decision to file Zydus’s section 505(b)(2) applications for apparent duplicates of DESCOVY and VEMLIDY and refuse to grant either of Zydus’s products an A-rating reflecting a determination of therapeutic equivalence, should such a determination become relevant. FDA-2026-P-10693 Exhibit 74 - ZYLOPRIM Approval Package Supporting & Related Material Background Material 2026-09-15T04:00:00Z 2026 9     2026-09-15T17:51:48Z   0 0 09000064b952448a
FDA-2026-P-10693-0086 FDA Requests that the FDA rescind their decision to file Zydus’s section 505(b)(2) applications for apparent duplicates of DESCOVY and VEMLIDY and refuse to grant either of Zydus’s products an A-rating reflecting a determination of therapeutic equivalence, should such a determination become relevant. FDA-2026-P-10693 Exhibit 73 - ALLOPURINOL Prescribing Information Supporting & Related Material Background Material 2026-09-15T04:00:00Z 2026 9     2026-09-15T17:51:44Z   0 0 09000064b9524489
FDA-2026-P-10693-0080 FDA Requests that the FDA rescind their decision to file Zydus’s section 505(b)(2) applications for apparent duplicates of DESCOVY and VEMLIDY and refuse to grant either of Zydus’s products an A-rating reflecting a determination of therapeutic equivalence, should such a determination become relevant. FDA-2026-P-10693 Exhibit 67 - FDA - Paragraph IV Patent Certifications Supporting & Related Material Background Material 2026-09-15T04:00:00Z 2026 9     2026-09-15T17:51:16Z   0 0 09000064b9524433
FDA-2026-P-10693-0073 FDA Requests that the FDA rescind their decision to file Zydus’s section 505(b)(2) applications for apparent duplicates of DESCOVY and VEMLIDY and refuse to grant either of Zydus’s products an A-rating reflecting a determination of therapeutic equivalence, should such a determination become relevant. FDA-2026-P-10693 Exhibit 60 - Cambridge English Dictionary - SUBSTANTIAL Supporting & Related Material Background Material 2026-09-15T04:00:00Z 2026 9     2026-09-15T17:50:51Z   0 0 09000064b952442c
FDA-2026-P-10693-0071 FDA Requests that the FDA rescind their decision to file Zydus’s section 505(b)(2) applications for apparent duplicates of DESCOVY and VEMLIDY and refuse to grant either of Zydus’s products an A-rating reflecting a determination of therapeutic equivalence, should such a determination become relevant. FDA-2026-P-10693 Exhibit 58 - Nakai - Detection of Hydrogen Atoms Using Only 3D ED MicroED Supporting & Related Material Background Material 2026-09-15T04:00:00Z 2026 9     2026-09-15T17:50:42Z   0 0 09000064b952442a
FDA-2026-P-10693-0065 FDA Requests that the FDA rescind their decision to file Zydus’s section 505(b)(2) applications for apparent duplicates of DESCOVY and VEMLIDY and refuse to grant either of Zydus’s products an A-rating reflecting a determination of therapeutic equivalence, should such a determination become relevant. FDA-2026-P-10693 Exhibit 52 - European Medicines Agency - Assessment Report for VEMLIDY - Excerpt Supporting & Related Material Background Material 2026-09-15T04:00:00Z 2026 9     2026-09-15T17:50:15Z   0 0 09000064b95243f2
FDA-2026-H-9606-0001 FDA DAB Civil Money Penalty; Georgia Weigant d/b/a Run-A-Muck Mercantile FDA-2026-H-9606 Complaint Other Complaint 2026-09-15T04:00:00Z 2026 9 2026-09-15T04:00:00Z   2026-09-15T19:26:41Z   0 0 09000064b955ac5c
FDA-2026-H-10582-0001 FDA DAB Civil Money Penalty; Little General Store, Inc., d/b/a Little General 2225 / Marathon FDA-2026-H-10582 Complaint Other Complaint 2026-09-15T04:00:00Z 2026 9 2026-09-15T04:00:00Z   2026-09-15T19:58:00Z   0 0 09000064b956163e
FDA-2026-P-9802-0009 FDA Requests that the FDA issue a declaration permitting the submission of an Abbreviated New Drug Application (ANDA) for Dabrafenib Capsules, 100 mg strength FDA-2026-P-9802 Attachment 1 - Proposed labeling Supporting & Related Material Background Material 2026-09-15T04:00:00Z 2026 9     2026-09-15T21:45:46Z   0 0 09000064b956167e
FDA-2026-H-10574-0001 FDA DAB Civil Money Penalty; Steinway Gourmet Deli Inc. d/b/a Steinway Gourmet Deli FDA-2026-H-10574 Complaint Other Complaint 2026-09-15T04:00:00Z 2026 9 2026-09-15T04:00:00Z   2026-09-15T18:03:27Z   0 0 09000064b955ede9
FDA-2026-N-1832-0053 FDA Generally Recognized as Safe (GRAS) Notices Filed in 2026 FDA-2026-N-1832 GRAS Notice (GRN) 1327 - Bifidobacterium breve GDMCC 62945 Notice General Notice 2026-09-15T04:00:00Z 2026 9 2026-09-15T04:00:00Z   2026-09-15T15:13:40Z   0 0 09000064b9554838
FDA-2026-P-10693-0063 FDA Requests that the FDA rescind their decision to file Zydus’s section 505(b)(2) applications for apparent duplicates of DESCOVY and VEMLIDY and refuse to grant either of Zydus’s products an A-rating reflecting a determination of therapeutic equivalence, should such a determination become relevant. FDA-2026-P-10693 Exhibit 50 - CONFIDENTIAL CMC Amendment Supporting & Related Material Background Material 2026-09-15T04:00:00Z 2026 9     2026-09-15T17:49:59Z   0 0 09000064b95243f0
FDA-2026-P-10693-0060 FDA Requests that the FDA rescind their decision to file Zydus’s section 505(b)(2) applications for apparent duplicates of DESCOVY and VEMLIDY and refuse to grant either of Zydus’s products an A-rating reflecting a determination of therapeutic equivalence, should such a determination become relevant. FDA-2026-P-10693 Exhibit 47 - Klein - Organic Chemistry - Excerpt Supporting & Related Material Background Material 2026-09-15T04:00:00Z 2026 9     2026-09-15T17:49:45Z   0 0 09000064b95243bb
FDA-2026-P-10693-0050 FDA Requests that the FDA rescind their decision to file Zydus’s section 505(b)(2) applications for apparent duplicates of DESCOVY and VEMLIDY and refuse to grant either of Zydus’s products an A-rating reflecting a determination of therapeutic equivalence, should such a determination become relevant. FDA-2026-P-10693 Exhibit 37 - European Medicines Agency Assessment Report Supporting & Related Material Background Material 2026-09-15T04:00:00Z 2026 9     2026-09-15T17:49:02Z   0 0 09000064b952437f
FDA-2026-P-10693-0049 FDA Requests that the FDA rescind their decision to file Zydus’s section 505(b)(2) applications for apparent duplicates of DESCOVY and VEMLIDY and refuse to grant either of Zydus’s products an A-rating reflecting a determination of therapeutic equivalence, should such a determination become relevant. FDA-2026-P-10693 Exhibit 36 - ODOMZO Prescribing Label Supporting & Related Material Background Material 2026-09-15T04:00:00Z 2026 9     2026-09-15T17:48:58Z   0 0 09000064b952437e
FDA-2026-P-10693-0041 FDA Requests that the FDA rescind their decision to file Zydus’s section 505(b)(2) applications for apparent duplicates of DESCOVY and VEMLIDY and refuse to grant either of Zydus’s products an A-rating reflecting a determination of therapeutic equivalence, should such a determination become relevant. FDA-2026-P-10693 Exhibit 28 - Drugs at FDA - TEKTURNA Supporting & Related Material Background Material 2026-09-15T04:00:00Z 2026 9     2026-09-15T17:48:11Z   0 0 09000064b9524376
FDA-2026-P-10693-0040 FDA Requests that the FDA rescind their decision to file Zydus’s section 505(b)(2) applications for apparent duplicates of DESCOVY and VEMLIDY and refuse to grant either of Zydus’s products an A-rating reflecting a determination of therapeutic equivalence, should such a determination become relevant. FDA-2026-P-10693 Exhibit 27 - Drugs at FDA - FAQs Supporting & Related Material Background Material 2026-09-15T04:00:00Z 2026 9     2026-09-15T17:48:06Z   0 0 09000064b9524325
FDA-2026-P-10693-0035 FDA Requests that the FDA rescind their decision to file Zydus’s section 505(b)(2) applications for apparent duplicates of DESCOVY and VEMLIDY and refuse to grant either of Zydus’s products an A-rating reflecting a determination of therapeutic equivalence, should such a determination become relevant. FDA-2026-P-10693 Exhibit 22 - Guidance - Naming of Drug Products Containing Salt Drug Substances Supporting & Related Material Background Material 2026-09-15T04:00:00Z 2026 9     2026-09-15T17:47:45Z   0 0 09000064b9524320
FDA-2026-P-10693-0027 FDA Requests that the FDA rescind their decision to file Zydus’s section 505(b)(2) applications for apparent duplicates of DESCOVY and VEMLIDY and refuse to grant either of Zydus’s products an A-rating reflecting a determination of therapeutic equivalence, should such a determination become relevant. FDA-2026-P-10693 Exhibit 14 - 68 Fed Reg 36676 Supporting & Related Material Background Material 2026-09-15T04:00:00Z 2026 9     2026-09-15T17:47:03Z   0 0 09000064b95242dc
FDA-2026-P-10693-0021 FDA Requests that the FDA rescind their decision to file Zydus’s section 505(b)(2) applications for apparent duplicates of DESCOVY and VEMLIDY and refuse to grant either of Zydus’s products an A-rating reflecting a determination of therapeutic equivalence, should such a determination become relevant. FDA-2026-P-10693 Exhibit 08 - Cheng - Tenofovir Alafenamide Fumarate Supporting & Related Material Background Material 2026-09-15T04:00:00Z 2026 9     2026-09-15T17:46:39Z   0 0 09000064b95242d6
FDA-2026-H-10580-0001 FDA DAB Civil Money Penalty; Aisha LLC, d/b/a Coventry Mart FDA-2026-H-10580 Complaint Other Complaint 2026-09-15T04:00:00Z 2026 9 2026-09-15T04:00:00Z   2026-09-16T00:31:43Z   0 0 09000064b955ac9f
FDA-2026-P-10779-0002 FDA Requests that the FDA determine and declare that Propylthiouracil Tablets, 100 mg and 150 mg is suitable for submission in an Abbreviated New Drug Application (ANDA) FDA-2026-P-10779 Acknowledgement Letter from FDA DMB to Quagen Pharmaceuticals LLC Other Acknowledgement Letter/Receipt 2026-09-15T04:00:00Z 2026 9 2026-09-15T04:00:00Z   2026-09-15T21:33:17Z   0 0 09000064b956165a
FDA-2026-P-10739-0005 FDA Request that the FDA declare that the drug product, Mirtazapine Tablet 5 mg is suitable for submission in an Abbreviated New Drug Application (ANDA) FDA-2026-P-10739 Attachment 3-Draft Package Insert Supporting & Related Material Background Material 2026-09-15T04:00:00Z 2026 9     2026-09-15T15:27:18Z   0 0 09000064b954f70d
FDA-2026-P-10739-0003 FDA Request that the FDA declare that the drug product, Mirtazapine Tablet 5 mg is suitable for submission in an Abbreviated New Drug Application (ANDA) FDA-2026-P-10739 Attachment 1-Orange book Supporting & Related Material Background Material 2026-09-15T04:00:00Z 2026 9     2026-09-15T15:27:12Z   0 0 09000064b954f6bf
FDA-2026-V-10397-0001 FDA Laser Light Show FDA-2026-V-10397 Variance Application from TMRW Sports Group, dba "TGL", "WTGL" Other Application for Variance (VAR) 2026-09-15T04:00:00Z 2026 9 2026-09-15T04:00:00Z   2026-09-15T17:28:39Z   0 0 09000064b94d05cb
FDA-2026-H-10496-0001 FDA DAB Civil Money Penalty; Jalaram United Inc. d/b/a Shell / Food Mart FDA-2026-H-10496 Complaint Other Complaint 2026-09-15T04:00:00Z 2026 9 2026-09-15T04:00:00Z   2026-09-15T20:56:13Z   0 0 09000064b9562374
FDA-2026-R-10632-0001 FDA DAB No Tobacco Sale Order; Central Park Grocery Corp. d/b/a Central Park Grocery FDA-2026-R-10632 Complaint Other Complaint 2026-09-15T04:00:00Z 2026 9 2026-09-15T04:00:00Z   2026-09-15T20:46:42Z   0 0 09000064b9561580
FDA-2026-H-10501-0001 FDA DAB Civil Money Penalty; Harry's Tobacco & Vape Outlet, Inc. d/b/a Harry's Tobacco & Vape Outlet FDA-2026-H-10501 Complaint Other Complaint 2026-09-15T04:00:00Z 2026 9 2026-09-15T04:00:00Z   2026-09-15T19:01:08Z   0 0 09000064b955210d
FDA-2026-P-10693-0009 FDA Requests that the FDA rescind their decision to file Zydus’s section 505(b)(2) applications for apparent duplicates of DESCOVY and VEMLIDY and refuse to grant either of Zydus’s products an A-rating reflecting a determination of therapeutic equivalence, should such a determination become relevant. FDA-2026-P-10693 Appendix 1 Exhibit 5 - Nakai 2025 Supporting & Related Material Background Material 2026-09-15T04:00:00Z 2026 9     2026-09-15T17:45:37Z   0 0 09000064b95244bd
FDA-2026-P-10693-0007 FDA Requests that the FDA rescind their decision to file Zydus’s section 505(b)(2) applications for apparent duplicates of DESCOVY and VEMLIDY and refuse to grant either of Zydus’s products an A-rating reflecting a determination of therapeutic equivalence, should such a determination become relevant. FDA-2026-P-10693 Appendix 1 Exhibit 3 - Bruhn 2021 Supporting & Related Material Background Material 2026-09-15T04:00:00Z 2026 9     2026-09-15T17:45:29Z   0 0 09000064b95244bb
FDA-2026-P-10693-0088 FDA Requests that the FDA rescind their decision to file Zydus’s section 505(b)(2) applications for apparent duplicates of DESCOVY and VEMLIDY and refuse to grant either of Zydus’s products an A-rating reflecting a determination of therapeutic equivalence, should such a determination become relevant. FDA-2026-P-10693 Exhibit 75 - LEVO-T Prescribing Information Supporting & Related Material Background Material 2026-09-15T04:00:00Z 2026 9     2026-09-15T17:51:51Z   0 0 09000064b952448b
FDA-2026-P-10693-0085 FDA Requests that the FDA rescind their decision to file Zydus’s section 505(b)(2) applications for apparent duplicates of DESCOVY and VEMLIDY and refuse to grant either of Zydus’s products an A-rating reflecting a determination of therapeutic equivalence, should such a determination become relevant. FDA-2026-P-10693 Exhibit 72 - Supplement Approval Letter for NDA 018832 Supporting & Related Material Background Material 2026-09-15T04:00:00Z 2026 9     2026-09-15T17:51:41Z   0 0 09000064b9524488
FDA-2026-P-10693-0077 FDA Requests that the FDA rescind their decision to file Zydus’s section 505(b)(2) applications for apparent duplicates of DESCOVY and VEMLIDY and refuse to grant either of Zydus’s products an A-rating reflecting a determination of therapeutic equivalence, should such a determination become relevant. FDA-2026-P-10693 Exhibit 64 - 41 Fed Reg 51085 Supporting & Related Material Background Material 2026-09-15T04:00:00Z 2026 9     2026-09-15T17:51:06Z   0 0 09000064b9524430
FDA-2026-P-10693-0076 FDA Requests that the FDA rescind their decision to file Zydus’s section 505(b)(2) applications for apparent duplicates of DESCOVY and VEMLIDY and refuse to grant either of Zydus’s products an A-rating reflecting a determination of therapeutic equivalence, should such a determination become relevant. FDA-2026-P-10693 Exhibit 63 - FDA Petition Response to Thomas A Hayes MD - Bristol-Myers Squibb Co Supporting & Related Material Background Material 2026-09-15T04:00:00Z 2026 9     2026-09-15T17:51:03Z   0 0 09000064b952442f
FDA-2026-P-10693-0068 FDA Requests that the FDA rescind their decision to file Zydus’s section 505(b)(2) applications for apparent duplicates of DESCOVY and VEMLIDY and refuse to grant either of Zydus’s products an A-rating reflecting a determination of therapeutic equivalence, should such a determination become relevant. FDA-2026-P-10693 Exhibit 55 - Reif Solid-state NMR spectroscopy Supporting & Related Material Background Material 2026-09-15T04:00:00Z 2026 9     2026-09-15T17:50:27Z   0 0 09000064b95243f5
FDA-2026-P-10693-0061 FDA Requests that the FDA rescind their decision to file Zydus’s section 505(b)(2) applications for apparent duplicates of DESCOVY and VEMLIDY and refuse to grant either of Zydus’s products an A-rating reflecting a determination of therapeutic equivalence, should such a determination become relevant. FDA-2026-P-10693 Exhibit 48 - CONFIDENTIAL GENVOYA NDA - Excerpt Supporting & Related Material Background Material 2026-09-15T04:00:00Z 2026 9     2026-09-15T17:49:51Z   0 0 09000064b95243ee
FDA-2026-P-10693-0055 FDA Requests that the FDA rescind their decision to file Zydus’s section 505(b)(2) applications for apparent duplicates of DESCOVY and VEMLIDY and refuse to grant either of Zydus’s products an A-rating reflecting a determination of therapeutic equivalence, should such a determination become relevant. FDA-2026-P-10693 Exhibit 42 - Orange Book 28th Ed - Excerpt Supporting & Related Material Background Material 2026-09-15T04:00:00Z 2026 9     2026-09-15T17:49:23Z   0 0 09000064b95243b6
FDA-2026-P-10693-0053 FDA Requests that the FDA rescind their decision to file Zydus’s section 505(b)(2) applications for apparent duplicates of DESCOVY and VEMLIDY and refuse to grant either of Zydus’s products an A-rating reflecting a determination of therapeutic equivalence, should such a determination become relevant. FDA-2026-P-10693 Exhibit 40 - AMA US Adopted Names Naming Guidelines Supporting & Related Material Background Material 2026-09-15T04:00:00Z 2026 9     2026-09-15T17:49:15Z   0 0 09000064b95243b4
FDA-2026-P-10693-0051 FDA Requests that the FDA rescind their decision to file Zydus’s section 505(b)(2) applications for apparent duplicates of DESCOVY and VEMLIDY and refuse to grant either of Zydus’s products an A-rating reflecting a determination of therapeutic equivalence, should such a determination become relevant. FDA-2026-P-10693 Exhibit 38 - Draft Guidance - Sameness Evaluation in ANDA Supporting & Related Material Background Material 2026-09-15T04:00:00Z 2026 9     2026-09-15T17:49:06Z   0 0 09000064b95243b2
FDA-2026-P-10693-0048 FDA Requests that the FDA rescind their decision to file Zydus’s section 505(b)(2) applications for apparent duplicates of DESCOVY and VEMLIDY and refuse to grant either of Zydus’s products an A-rating reflecting a determination of therapeutic equivalence, should such a determination become relevant. FDA-2026-P-10693 Exhibit 35 - CONFIDENTIAL Letter from FDA to Gilead Supporting & Related Material Background Material 2026-09-15T04:00:00Z 2026 9     2026-09-15T17:48:42Z   0 0 09000064b952437d
FDA-2026-P-10693-0044 FDA Requests that the FDA rescind their decision to file Zydus’s section 505(b)(2) applications for apparent duplicates of DESCOVY and VEMLIDY and refuse to grant either of Zydus’s products an A-rating reflecting a determination of therapeutic equivalence, should such a determination become relevant. FDA-2026-P-10693 Exhibit 31 - Draft Guidance - Daclatasvir Dihydrochloride Supporting & Related Material Background Material 2026-09-15T04:00:00Z 2026 9     2026-09-15T17:48:24Z   0 0 09000064b9524379
FDA-2026-P-10693-0034 FDA Requests that the FDA rescind their decision to file Zydus’s section 505(b)(2) applications for apparent duplicates of DESCOVY and VEMLIDY and refuse to grant either of Zydus’s products an A-rating reflecting a determination of therapeutic equivalence, should such a determination become relevant. FDA-2026-P-10693 Exhibit 21 - VEMLIDY Container Label Supporting & Related Material Background Material 2026-09-15T04:00:00Z 2026 9     2026-09-15T17:47:41Z   0 0 09000064b952431f
FDA-2026-P-10693-0030 FDA Requests that the FDA rescind their decision to file Zydus’s section 505(b)(2) applications for apparent duplicates of DESCOVY and VEMLIDY and refuse to grant either of Zydus’s products an A-rating reflecting a determination of therapeutic equivalence, should such a determination become relevant. FDA-2026-P-10693 Exhibit 17 - 54 Fed Reg 28872 Supporting & Related Material Background Material 2026-09-15T04:00:00Z 2026 9     2026-09-15T17:47:25Z   0 0 09000064b95242df
FDA-2026-P-10693-0024 FDA Requests that the FDA rescind their decision to file Zydus’s section 505(b)(2) applications for apparent duplicates of DESCOVY and VEMLIDY and refuse to grant either of Zydus’s products an A-rating reflecting a determination of therapeutic equivalence, should such a determination become relevant. FDA-2026-P-10693 Exhibit 11 - Guidance - Determining Whether to Submit an ANDA Supporting & Related Material Background Material 2026-09-15T04:00:00Z 2026 9     2026-09-15T17:46:51Z   0 0 09000064b95242d9
FDA-2026-P-10693-0014 FDA Requests that the FDA rescind their decision to file Zydus’s section 505(b)(2) applications for apparent duplicates of DESCOVY and VEMLIDY and refuse to grant either of Zydus’s products an A-rating reflecting a determination of therapeutic equivalence, should such a determination become relevant. FDA-2026-P-10693 Exhibit 01 - FDA - Approval Letter for DESCOVY Supporting & Related Material Background Material 2026-09-15T04:00:00Z 2026 9     2026-09-15T17:46:10Z   0 0 09000064b951d4fd
FDA-2023-V-0784-0005 FDA Laser Light Show FDA-2023-V-0784 Variance Renewal Approval Letter from FDA CDRH to Dawnpatrol LLC Other Approval for Variance (VRA) 2026-09-15T04:00:00Z 2026 9 2026-09-15T04:00:00Z   2026-09-16T00:26:58Z   0 0 09000064b955bc28
FDA-2026-P-10785-0002 FDA Requests that the FDA declare that the drug products Famotidine Capsules, 20 mg and 40 mg, are suitable for consideration in an Abbreviated New Drug Application. FDA-2026-P-10785 Acknowledgement Letter from FDA DMB to Hyman, Phelps & McNamara, P.C. Other Acknowledgement Letter/Receipt 2026-09-15T04:00:00Z 2026 9 2026-09-15T04:00:00Z   2026-09-16T00:12:00Z   0 0 09000064b9562c0d
FDA-2024-V-2018-0004 FDA Laser Light Show FDA-2024-V-2018 Variance Renewal from Dorsal Entertainment LLC Other Application for Variance (VAR) 2026-09-15T04:00:00Z 2026 9 2026-09-15T04:00:00Z   2026-09-16T00:14:46Z   0 0 09000064b955bc2c
FDA-2026-H-10579-0001 FDA DAB Civil Money Penalty; Eablad LLC, d/b/a Shell / Food Mart FDA-2026-H-10579 Complaint Other Complaint 2026-09-15T04:00:00Z 2026 9 2026-09-15T04:00:00Z   2026-09-15T19:30:08Z   0 0 09000064b9560705
FDA-2026-H-10569-0001 FDA DAB Civil Money Penalty; Delicious Deli I Corp. d/b/a Catherine Deli & Bagels FDA-2026-H-10569 Complaint Other Complaint 2026-09-15T04:00:00Z 2026 9 2026-09-15T04:00:00Z   2026-09-15T17:38:31Z   0 0 09000064b955aeac
FDA-2026-H-10571-0001 FDA DAB Civil Money Penalty; Mill Street Mart Inc. d/b/a Mill Street Mart Inc. FDA-2026-H-10571 Complaint Other Complaint 2026-09-15T04:00:00Z 2026 9 2026-09-15T04:00:00Z   2026-09-15T19:23:31Z   0 0 09000064b955efc2
FDA-2024-P-1871-0015 FDA Requests the Commissioner to ensure that applications submitted under 505(j) and 505(b)(2) that rely on Lutathera include data necessary to show that a proposed product is pharmaceutically equivalent, bioequivalent, and can be expected to have the same clinical effect and safety profile as Lutathera when administered to patients under the conditions specified in the labeling FDA-2024-P-1871 Reconsideration Response Other Letter(s) 2026-09-15T04:00:00Z 2026 9 2026-09-15T04:00:00Z   2026-09-15T19:17:41Z   0 0 09000064b9554926
FDA-2026-H-10583-0001 FDA DAB Civil Money Penalty; Pic N Tote Two LLC, d/b/a Pic N Tote / VP Racing Fuels FDA-2026-H-10583 Complaint Other Complaint 2026-09-15T04:00:00Z 2026 9 2026-09-15T04:00:00Z   2026-09-15T19:59:11Z   0 0 09000064b9561655
FDA-2026-H-10577-0001 FDA DAB Civil Money Penalty; Lake Life Petro LLC, d/b/a Jacksonville Marathon FDA-2026-H-10577 Complaint Other Complaint 2026-09-15T04:00:00Z 2026 9 2026-09-15T04:00:00Z   2026-09-15T18:51:22Z   0 0 09000064b9557ee1
FDA-2026-P-10693-0012 FDA Requests that the FDA rescind their decision to file Zydus’s section 505(b)(2) applications for apparent duplicates of DESCOVY and VEMLIDY and refuse to grant either of Zydus’s products an A-rating reflecting a determination of therapeutic equivalence, should such a determination become relevant. FDA-2026-P-10693 Appendix 1 Exhibit 8 - Clabbers 2022 Supporting & Related Material Background Material 2026-09-15T04:00:00Z 2026 9     2026-09-15T17:45:49Z   0 0 09000064b9525938
FDA-2026-P-10693-0091 FDA Requests that the FDA rescind their decision to file Zydus’s section 505(b)(2) applications for apparent duplicates of DESCOVY and VEMLIDY and refuse to grant either of Zydus’s products an A-rating reflecting a determination of therapeutic equivalence, should such a determination become relevant. FDA-2026-P-10693 Exhibit 78 - Guidance - Evaluation of Therapeutic Equivalence Supporting & Related Material Background Material 2026-09-15T04:00:00Z 2026 9     2026-09-15T17:52:03Z   0 0 09000064b95244b6
FDA-2026-P-10693-0081 FDA Requests that the FDA rescind their decision to file Zydus’s section 505(b)(2) applications for apparent duplicates of DESCOVY and VEMLIDY and refuse to grant either of Zydus’s products an A-rating reflecting a determination of therapeutic equivalence, should such a determination become relevant. FDA-2026-P-10693 Exhibit 68 - Draft Guidance - Safety Labeling Changes Supporting & Related Material Background Material 2026-09-15T04:00:00Z 2026 9     2026-09-15T17:51:20Z   0 0 09000064b9524484
FDA-2026-P-10693-0078 FDA Requests that the FDA rescind their decision to file Zydus’s section 505(b)(2) applications for apparent duplicates of DESCOVY and VEMLIDY and refuse to grant either of Zydus’s products an A-rating reflecting a determination of therapeutic equivalence, should such a determination become relevant. FDA-2026-P-10693 Exhibit 65 - FDA Petition Response to Scott H Korn MD FACP - Merck Sharpe Dohme Corp Supporting & Related Material Background Material 2026-09-15T04:00:00Z 2026 9     2026-09-15T17:51:09Z   0 0 09000064b9524431
FDA-2026-P-10693-0066 FDA Requests that the FDA rescind their decision to file Zydus’s section 505(b)(2) applications for apparent duplicates of DESCOVY and VEMLIDY and refuse to grant either of Zydus’s products an A-rating reflecting a determination of therapeutic equivalence, should such a determination become relevant. FDA-2026-P-10693 Exhibit 53 - Newman From Powders to Single Crystals Supporting & Related Material Background Material 2026-09-15T04:00:00Z 2026 9     2026-09-15T17:50:19Z   0 0 09000064b95243f3
FDA-2026-P-10693-0059 FDA Requests that the FDA rescind their decision to file Zydus’s section 505(b)(2) applications for apparent duplicates of DESCOVY and VEMLIDY and refuse to grant either of Zydus’s products an A-rating reflecting a determination of therapeutic equivalence, should such a determination become relevant. FDA-2026-P-10693 Exhibit 46 - Cruz-Cabeza - The Role of Solvation in Proton Transfer Reactions Supporting & Related Material Background Material 2026-09-15T04:00:00Z 2026 9     2026-09-15T17:49:39Z   0 0 09000064b95243ba
FDA-2026-P-10693-0057 FDA Requests that the FDA rescind their decision to file Zydus’s section 505(b)(2) applications for apparent duplicates of DESCOVY and VEMLIDY and refuse to grant either of Zydus’s products an A-rating reflecting a determination of therapeutic equivalence, should such a determination become relevant. FDA-2026-P-10693 Exhibit 44 - Novartis Pharmaceuticals Corporation v Becerra Supporting & Related Material Background Material 2026-09-15T04:00:00Z 2026 9     2026-09-15T17:49:31Z   0 0 09000064b95243b8
FDA-2026-P-10693-0054 FDA Requests that the FDA rescind their decision to file Zydus’s section 505(b)(2) applications for apparent duplicates of DESCOVY and VEMLIDY and refuse to grant either of Zydus’s products an A-rating reflecting a determination of therapeutic equivalence, should such a determination become relevant. FDA-2026-P-10693 Exhibit 41 - WHO Guidance - Use of INNs Supporting & Related Material Background Material 2026-09-15T04:00:00Z 2026 9     2026-09-15T17:49:19Z   0 0 09000064b95243b5
FDA-2026-P-10693-0045 FDA Requests that the FDA rescind their decision to file Zydus’s section 505(b)(2) applications for apparent duplicates of DESCOVY and VEMLIDY and refuse to grant either of Zydus’s products an A-rating reflecting a determination of therapeutic equivalence, should such a determination become relevant. FDA-2026-P-10693 Exhibit 32 - CDER Chemistry Review for NDA 208215 DESCOVY - Excerpt Supporting & Related Material Background Material 2026-09-15T04:00:00Z 2026 9     2026-09-15T17:48:27Z   0 0 09000064b952437a
FDA-2026-P-10693-0037 FDA Requests that the FDA rescind their decision to file Zydus’s section 505(b)(2) applications for apparent duplicates of DESCOVY and VEMLIDY and refuse to grant either of Zydus’s products an A-rating reflecting a determination of therapeutic equivalence, should such a determination become relevant. FDA-2026-P-10693 Exhibit 24 - TEKTURNA Prescribing Information Supporting & Related Material Background Material 2026-09-15T04:00:00Z 2026 9     2026-09-15T17:47:53Z   0 0 09000064b9524322
FDA-2026-P-10693-0029 FDA Requests that the FDA rescind their decision to file Zydus’s section 505(b)(2) applications for apparent duplicates of DESCOVY and VEMLIDY and refuse to grant either of Zydus’s products an A-rating reflecting a determination of therapeutic equivalence, should such a determination become relevant. FDA-2026-P-10693 Exhibit 16 - Guidance - Regulatory Classification of Pharmaceutical Co-Crystals Supporting & Related Material Background Material 2026-09-15T04:00:00Z 2026 9     2026-09-15T17:47:20Z   0 0 09000064b95242de
FDA-2026-P-10693-0026 FDA Requests that the FDA rescind their decision to file Zydus’s section 505(b)(2) applications for apparent duplicates of DESCOVY and VEMLIDY and refuse to grant either of Zydus’s products an A-rating reflecting a determination of therapeutic equivalence, should such a determination become relevant. FDA-2026-P-10693 Exhibit 13 - Draft Guidance - Applications Covered by Section 505 Supporting & Related Material Background Material 2026-09-15T04:00:00Z 2026 9     2026-09-15T17:46:59Z   0 0 09000064b95242db
FDA-2026-P-10693-0025 FDA Requests that the FDA rescind their decision to file Zydus’s section 505(b)(2) applications for apparent duplicates of DESCOVY and VEMLIDY and refuse to grant either of Zydus’s products an A-rating reflecting a determination of therapeutic equivalence, should such a determination become relevant. FDA-2026-P-10693 Exhibit 12 - Draft Guidance - Determining Whether to Submit an ANDA Supporting & Related Material Background Material 2026-09-15T04:00:00Z 2026 9     2026-09-15T17:46:55Z   0 0 09000064b95242da
FDA-2026-H-10570-0001 FDA DAB Civil Money Penalty; Hannibal Sandy’s, Inc. d/b/a BP / To Go FDA-2026-H-10570 Complaint Other Complaint 2026-09-15T04:00:00Z 2026 9 2026-09-15T04:00:00Z   2026-09-15T18:16:47Z   0 0 09000064b955edfa
FDA-2026-N-1832-0052 FDA Generally Recognized as Safe (GRAS) Notices Filed in 2026 FDA-2026-N-1832 GRAS Notice (GRN) 1291 - Amendments - Wattle (Acacia longifolia) seeds Notice General Notice 2026-09-15T04:00:00Z 2026 9 2026-09-15T04:00:00Z   2026-09-15T15:13:34Z   0 0 09000064b9554837
FDA-2026-N-10165-0001 FDA Statistical Considerations for Rare Disease Clinical Investigations; Establishment of a Public Docket; Request for Information and Comments FDA-2026-N-10165 Statistical Considerations for the Design of Rare Disease Clinical Investigations; Establishment of a Public Docket; Request for Information and Comments Notice Request for Comments 2026-09-15T04:00:00Z 2026 9 2026-09-15T04:00:00Z 2026-11-14T04:59:59Z 2026-09-15T17:15:44Z 2026-18805 1 0 09000064b955afbc
FDA-2026-V-10397-0002 FDA Laser Light Show FDA-2026-V-10397 Acknowledgment Letter from FDA DMB to TMRW Sports Group, dba "TGL", "WTGL" Other Acknowledgement Letter/Receipt 2026-09-15T04:00:00Z 2026 9 2026-09-15T04:00:00Z   2026-09-15T17:28:51Z   0 0 09000064b94d0682
FDA-2024-V-2018-0005 FDA Laser Light Show FDA-2024-V-2018 Variance Renewal Approval Letter from FDA CDRH to Dorsal Entertainment LLC Other Approval for Variance (VRA) 2026-09-15T04:00:00Z 2026 9 2026-09-15T04:00:00Z   2026-09-16T00:15:06Z   0 0 09000064b955bc27
FDA-2025-P-1807-0368 FDA Petition for Reclassification of Covid-19 mRNA And Adenoviral Vector Products as Gene Therapy Products and for Regulatory Action Regarding the Statutory Violations and International Legal Contraventions Inherent in the Covid-19 Countermeasures Program FDA-2025-P-1807 Response Letter Other Response(s) 2026-09-15T04:00:00Z 2026 9 2026-09-15T04:00:00Z   2026-09-15T19:11:17Z   0 0 09000064b955ee1b
FDA-2016-N-3120-0584 FDA Kremers Urban Pharmaceuticals Inc.; Proposal to Withdraw Approval of an Abbreviated New Drug Application for Extended-Release Methylphenidate Tablets FDA-2016-N-3120 Notice of Entry of Appearance Other Appearance Request 2026-09-15T04:00:00Z 2026 9 2026-09-15T04:00:00Z   2026-09-15T19:09:30Z   0 0 09000064b95549cb
FDA-2026-P-10779-0005 FDA Requests that the FDA determine and declare that Propylthiouracil Tablets, 100 mg and 150 mg is suitable for submission in an Abbreviated New Drug Application (ANDA) FDA-2026-P-10779 Attachment 2 - RLD Labeling Supporting & Related Material Background Material 2026-09-15T04:00:00Z 2026 9     2026-09-15T21:33:29Z   0 0 09000064b9562c0a
FDA-2026-P-10779-0003 FDA Requests that the FDA determine and declare that Propylthiouracil Tablets, 100 mg and 150 mg is suitable for submission in an Abbreviated New Drug Application (ANDA) FDA-2026-P-10779 Table of Contents Supporting & Related Material Background Material 2026-09-15T04:00:00Z 2026 9     2026-09-15T21:33:23Z   0 0 09000064b955efca
FDA-2026-P-10785-0004 FDA Requests that the FDA declare that the drug products Famotidine Capsules, 20 mg and 40 mg, are suitable for consideration in an Abbreviated New Drug Application. FDA-2026-P-10785 Attachment 2 Supporting & Related Material Background Material 2026-09-15T04:00:00Z 2026 9     2026-09-16T00:12:06Z   0 0 09000064b956070a
FDA-2026-P-10693-0001 FDA Requests that the FDA rescind their decision to file Zydus’s section 505(b)(2) applications for apparent duplicates of DESCOVY and VEMLIDY and refuse to grant either of Zydus’s products an A-rating reflecting a determination of therapeutic equivalence, should such a determination become relevant. FDA-2026-P-10693 Citizen Petition from Gilead Sciences, Inc. Other Citizen Petition 2026-09-15T04:00:00Z 2026 9 2026-09-15T04:00:00Z   2026-09-15T17:44:40Z   1 0 09000064b9523a58
FDA-2026-V-10397-0003 FDA Laser Light Show FDA-2026-V-10397 Variance Approval Letter from FDA CDRH to TMRW Sports Group, dba "TGL", "WTGL" Other Approval for Variance (VRA) 2026-09-15T04:00:00Z 2026 9 2026-09-15T04:00:00Z   2026-09-15T17:28:58Z   0 0 09000064b955bc35

Next page

Advanced export

JSON shape: default, array, newline-delimited, object

CSV options:

CREATE TABLE documents (
    id TEXT PRIMARY KEY,
    agency_id TEXT,
    docket_id TEXT REFERENCES dockets(id),
    title TEXT,
    document_type TEXT,
    subtype TEXT,
    posted_date TEXT,
    posted_year INTEGER,
    posted_month INTEGER,
    comment_start_date TEXT,
    comment_end_date TEXT,
    last_modified TEXT,
    fr_doc_num TEXT,
    open_for_comment INTEGER,
    withdrawn INTEGER,
    object_id TEXT
);
CREATE INDEX idx_docs_agency ON documents(agency_id);
CREATE INDEX idx_docs_docket ON documents(docket_id);
CREATE INDEX idx_docs_date ON documents(posted_date);
CREATE INDEX idx_docs_year ON documents(posted_year);
CREATE INDEX idx_docs_type ON documents(document_type);
CREATE INDEX idx_docs_frnum ON documents(fr_doc_num);
CREATE INDEX idx_docs_comment_end ON documents(comment_end_date) WHERE comment_end_date IS NOT NULL AND withdrawn = 0;
Powered by Datasette · Queries took 130.677ms · Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API · Privacy